Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31219310 | 1.00 | LPL (0.47) | LPLLIPGDGAT1IRAK4CA1 | |
| SCHEMBL19794333 | 0.87 | DGAT1 (0.55) | LPLLIPGDGAT1IRAK4CA1 | |
| SCHEMBL16189291 | 0.86 | LIPG (0.59) | LPLLIPGDGAT1IRAK4CA1 | |
| SCHEMBL20068614 | 0.82 | DGAT1 (0.56) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL16158904 | 0.82 | CA1 (0.47) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL506215 | 0.79 | DGAT1 (0.47) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL39898 | 0.79 | LPL (0.46) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL17787570 | 0.79 | LPL (0.46) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL1602392 | 0.79 | LPL (0.46) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL16278109 | 0.79 | LPL (0.46) | LPLLIPGDGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-12540139-B2 | Imidazopiperazine inhibitors of transcription activating proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4653053-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2025-10-16 | — | — | US | disclosed |
| EP-4426434-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-19 | — | — | US | disclosed |
| EP-1888523-A2 | CYCLOBUTYL AMINE DERIVATIVES | Abbott Laboratories (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7323467-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-01-29 | — | — | US | disclosed |
| US-20070219202-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2007-09-20 | — | — | US | disclosed |
| US-7235554-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | SANOFI-AVENTIS (FR) | 2007-06-26 | — | — | US | disclosed |
| US-20070078133-A1 | Cyclobutyl amine derivatives | ABBVIE INC. | 2007-04-05 | — | — | US | disclosed |
| WO-2006132914-A2 | CYCLOBUTYL AMINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1492792-B1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO¬4,5-B|INDOLE-1-ACETAMIDE DERIVATIVES, PREPARATION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | EP | disclosed |
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | SANOFI (FR) | 2005-06-09 | — | — | US | disclosed |
| EP-1492792-A2 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO 4,5-B]INDOLE-1-ACETAMIDE DERIVATIVES, PREPARATION AND USE THEREOF IN MEDICAMENTS | Sanofi-Aventis (FR) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082874-A2 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-ACETAMIDE DERIVATIVES, PREPARATION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS (FR) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124615-A1 | 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments | HRH4, IDO1, HTR4 | LPL 4718/4885LIPG 4819/4885DGAT1 3714/4885 |
| US-12540139-B2 | Imidazopiperazine inhibitors of transcription activating proteins | EP300, BRPF3, CREBBP | LPL 1674/4885LIPG 3702/4885DGAT1 2768/4885 |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | LPL 4698/4885LIPG 3607/4885DGAT1 3998/4885 |
| US-20070219202-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics | IDO1, IDO2, TPH1 | LPL 4256/4885LIPG 3892/4885DGAT1 2439/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | LPL 2/4885LIPG 17/4885DGAT1 70/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | LPL 4355/4885LIPG 4527/4885DGAT1 2310/4885 |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | ATR, CHEK1, CHEK2 | LPL 4701/4885LIPG 3578/4885DGAT1 3977/4885 |
| US-20070078133-A1 | Cyclobutyl amine derivatives | HRH2, HRH4, HRH3 | LPL 2808/4885LIPG 1672/4885DGAT1 4183/4885 |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | LPL 164/4885LIPG 514/4885DGAT1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.